title: Paediatric reduced intensity conditioning: analysis of centre strategies on regimens and definitions by the EBMT Paediatric Diseases and Complications and Quality of Life WP.
abstract: The aim of this analysis was to explore the diversity of reduced intensity conditioning (RIC) in paediatric allo-SCT in daily practice across Europe. Data from the European Group for Blood and Marrow Transplantation (EBMT) Promise database from 1994 to 2008 were supplemented by a survey of EBMT centres performing paediatric allo-SCT on the current policy asking for the underlying diseases and for the drug combinations. Records from 161 centres from 30 countries were analysed and 139 various RIC regimens were reported. More centres applied RIC for malignant rather than for non-malignant diseases. In general, fludarabine (FLU)-based regimens predominated except for BU-based regimens in myeloid malignancies and haemoglobinopathies. Treosulfan (TREO) was mainly applied for unspecified malignant diseases and for haemophagocytic diseases. FLU-based regimens revealed the greatest number of different combinations. Correlating the number of regimens with the number of treating centres revealed the lowest variety in FLU and the highest variety in TBI and TREO. FLU/melphalane and FLU/CY were the most frequent combinations. This extreme heterogeneity in RIC may influence both the efficacy and the safety of the procedures, which requires further investigation. Optimization and standardization of RIC is the final goal to provide a platform for future prospective studies.
authors.affiliation: St Anna Children's Hospital, SCT Unit, Medical University Vienna, Vienna, Austria.
authors.forename: A
authors.initials: A
authors.lastname: Lawitschka
authors.affiliation: Bone Marrow Transplantation Unit, Department of Haematology-Oncology, G. Gaslini Children's Research Institute, Genova, Italy.
authors.forename: M
authors.initials: M
authors.lastname: Faraci
authors.affiliation: Department of Paediatric Haematology Oncology and BMT Unit, Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
authors.forename: I
authors.initials: I
authors.lastname: Yaniv
authors.affiliation: Department of BMT, Great Ormond Street Hospital for Children NHS Trust, London, UK.
authors.forename: P
authors.initials: P
authors.lastname: Veys
authors.affiliation: Division for Stem Cell Transplantation, University Children's Hospital, Frankfurt/Main, Germany.
authors.forename: P
authors.initials: P
authors.lastname: Bader
authors.affiliation: Department of Paediatric Oncology, Haematology and Transplantology, University of Medical Sciences, Poznañ, Poland.
authors.forename: J
authors.initials: J
authors.lastname: Wachowiak
authors.affiliation: Service d'Hematologie-Greffe de Moelle, Hopital Saint Louis, Paris, France.
authors.forename: G
authors.initials: G
authors.lastname: Socie
authors.affiliation: HSCT Program, Oncology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
authors.forename: M D
authors.initials: MD
authors.lastname: Aljurf
authors.affiliation: Department of Haematology, Ankara University Faculty of Medicine, Ankara, Turkey.
authors.forename: M
authors.initials: M
authors.lastname: Arat
authors.affiliation: University Medical Center Utrecht, Paediatric Blood and Marrow Transplantation Program, Utrecht, The Netherlands.
authors.forename: J J
authors.initials: JJ
authors.lastname: Boelens
authors.affiliation: Department of Haematology, ICO-Hospital Duran i Reynals, Barcelona, Spain.
authors.forename: R
authors.initials: R
authors.lastname: Duarte
authors.affiliation: Department of Haematology, University Hospital Haematology Petersgraben, Basel, Switzerland.
authors.forename: A
authors.initials: A
authors.lastname: Tichelli
authors.affiliation: St Anna Children's Hospital, SCT Unit, Medical University Vienna, Vienna, Austria.
authors.forename: C
authors.identifier: 0000000303698515
authors.initials: C
authors.lastname: Peters
mesh_terms: D000293:Adolescent; D064591:Allografts; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage; D002066:Busulfan / Q000008:administration & dosage / Q000031:analogs & derivatives; D002648:Child; D002675:Child, Preschool; D016208:Databases, Factual; D005260:Female; D006402:Hematologic Diseases / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008297:Male; D019653:Myeloablative Agonists / Q000008:administration & dosage; D011787:Quality of Health Care; D011788:Quality of Life; D012189:Retrospective Studies; D019172:Transplantation Conditioning / Q000379:methods*; D014740:Vidarabine / Q000008:administration & dosage / Q000031:analogs & derivatives
chemical_list: D018906:Antineoplastic Agents, Alkylating; D019653:Myeloablative Agonists; C018404:treosulfan; D014740:Vidarabine; D002066:Busulfan; C024352:fludarabine